Automated and Decentralized Genomic Profiling of Plasma Cell-Free DNA for Identification of Targetable and Resistance Alterations in Advanced Solid Tumors
Clinical Chemistry · 2025
DOI: 10.1093/clinchem/hvaf045 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Chemistry, 2025. Verfasst von Hiu Ting Chan und 15 weiteren Autor:innen. Beteiligte Einrichtung: Project for Development of Liquid Biopsy Diagnosis, Cancer Precision Medicine Center, Japanese Foundation for Cancer Research, Tokyo, Japan. Hauptthemen laut MEDLINE: Neoplasms, Cell-Free Nucleic Acids, Circulating Tumor DNA, Drug Resistance, Neoplasm. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Existing circulating cell-free DNA (cfDNA) assays are primarily centralized, requiring specialized sample handling and transportation. Implementing a flexible, decentralized sequencing system at point of care, with minimal technical oversight, can enhance turnaround times and patient access to genomic profiling. In this study, we aimed to evaluate the clinical feasibility of an automated and decentralized cfDNA next-generation sequencing (NGS) assay for identifying actionable alterations in advanced solid tumors.
Methods
Genomic profiling of plasma cfDNA from 298 patients with advanced solid tumors was conducted using an automated NGS assay. We assessed concordance of tumor mutations detected in plasma cfDNA and patient-matched tumor tissues analyzed by an FDA-approved assay, investigating clinical factors influencing circulating tumor DNA (ctDNA) aberration (mut-ctDNA) detection sensitivity.
Results
Sequencing success rates for cfDNA genomic profiling was significantly higher than archived tumor tissue (99% vs 96%). Mut-ctDNA detection rates ranged from 20% to 67% across different solid tumors. Targetable or resistance alterations were found in 18% of the patients. About 72% of the patients showed concordant alterations from tissue and plasma. The level of concordance was associated with the cancer type, tumor burden, and metastatic location. Notably, 63 plasma-only alterations were identified in 18% of patients and were more frequently observed in those with prior targeted treatments (24%) compared to chemotherapy (10%).
Conclusions
This study underscores the clinical feasibility of an automated, decentralized cfDNA genomic profiling approach. It emphasizes the importance of considering confounding clinical factors when selecting plasma- or tissue-based profiling assay. Such an approach holds promise for enhancing patient access to timely genomic profiling and targeted therapy selection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Project for Development of Liquid Biopsy Diagnosis, Cancer Precision Medicine Center, Japanese Foundation for Cancer Research, Tokyo, Japan.
- Precision Oncology Group, Collaborative Centre for Genomic Cancer Medicine, Department of Clinical Pathology, Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Victoria Australia.
- Department of Medical Oncology, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan.
- Department of Clinical Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan.
- Department of Genomic Medicine, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan.
- Department of Breast Medical Oncology, Breast Oncology Center, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan.
ORCID-Profile: Hiu Ting Chan, Naoki Fukuda, Mayu Yunokawa, Kensei Yamaguchi, Shunji Takahashi, Siew-Kee Low
Zitieren
APA
Chan, H. T., Otaki, M., Hayashi, N., Fukada, I., Chin, Y. M., Fukuda, N., Hosonaga, M., Wang, X., Yunokawa, M., Shinozaki, E., Yamaguchi, K., Wakatsuki, T., Kasuga, A., Nakamura, Y., Takahashi, S., & Low, S. K. (2025). Automated and Decentralized Genomic Profiling of Plasma Cell-Free DNA for Identification of Targetable and Resistance Alterations in Advanced Solid Tumors. Clinical Chemistry. https://doi.org/10.1093/clinchem/hvaf045
Vancouver
Chan HT, Otaki M, Hayashi N, Fukada I, Chin YM, Fukuda N, et al. Automated and Decentralized Genomic Profiling of Plasma Cell-Free DNA for Identification of Targetable and Resistance Alterations in Advanced Solid Tumors. Clinical Chemistry. 2025. doi:10.1093/clinchem/hvaf045
BibTeX
@article{Chan2025,
author = {Chan, Hiu Ting and Otaki, Masumi and Hayashi, Naomi and Fukada, Ippei and Chin, Yoon Ming and Fukuda, Naoki and Hosonaga, Mari and Wang, Xiaofei and Yunokawa, Mayu and Shinozaki, Eiji and Yamaguchi, Kensei and Wakatsuki, Takeru and Kasuga, Akiyoshi and Nakamura, Yusuke and Takahashi, Shunji and Low, Siew-Kee},
title = {Automated and Decentralized Genomic Profiling of Plasma Cell-Free DNA for Identification of Targetable and Resistance Alterations in Advanced Solid Tumors},
journal = {Clinical Chemistry},
year = {2025},
doi = {10.1093/clinchem/hvaf045}
}
EUVIMED